KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Esperion Therapeutics (ESPR) Cost of Revenue (2020 - 2025)

Esperion Therapeutics' Cost of Revenue history spans 6 years, with the latest figure at $41.3 million for Q3 2025.

  • For Q3 2025, Cost of Revenue rose 138.86% year-over-year to $41.3 million; the TTM value through Sep 2025 reached $127.0 million, up 133.36%, while the annual FY2024 figure was $68.6 million, 58.55% up from the prior year.
  • Cost of Revenue reached $41.3 million in Q3 2025 per ESPR's latest filing, up from $28.5 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $41.3 million in Q3 2025 to a low of $1.8 million in Q1 2021.
  • Average Cost of Revenue over 5 years is $13.4 million, with a median of $10.1 million recorded in 2024.
  • Peak YoY movement for Cost of Revenue: skyrocketed 5654.84% in 2021, then fell 26.05% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $5.1 million in 2021, then decreased by 18.03% to $4.2 million in 2022, then skyrocketed by 175.29% to $11.5 million in 2023, then soared by 123.81% to $25.6 million in 2024, then surged by 61.09% to $41.3 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Cost of Revenue are $41.3 million (Q3 2025), $28.5 million (Q2 2025), and $31.5 million (Q1 2025).